Current Price
Target Price
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2024 | FY 2024 | FY 2024 | FY 2025 | FY 2025 | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-0.30 | $0.60 | $-0.09 | $-0.24 | $-0.18 | $-0.07 | $-0.09 | — | $-0.50 | $-0.50 | |
| 0.01 | 0.11 | 0.02 | 0 | 0 | 0.02 | 0.01 | 0 | 0.09 | 0.09 | |
| -3.4% | -3.2% | +24.3% | -70.3% | +0.0% | +53.3% | -28.6% | — | -1.0% | -1.0% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | AApnimed In... | APMD | $704.39M | 2.34 | 4.40 | 142.10% | 31.20% | — | -29.40% |
| 2. | RRigel Phar... | RIGL | $837.18M | 2.77 | 1.88 | 106.60% | 26.30% | 109.20% | 16.50% |
| 3. | IInnoviva I... | INVA | $1.35B | 8.10 | 1.19 | 44.10% | 39.50% | 18.00% | -1.60% |
| 4. | TTheravance... | TBPH | $884.18M | 16.38 | 3.05 | 51.60% | 8.89% | 20.90% | -20.90% |
| 5. | AAurinia Ph... | AUPH | $2.11B | 6.90 | 3.21 | 97.70% | 51.60% | 61.40% | 13.90% |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 |
|---|---|---|---|---|---|---|---|---|
Revenue | 22.57 | 12.37 | 14.44 | 493.9 | 14.47 | 0.89 | 1.25 | 493.9 |
COGS | 53.6 | 41.69 | 40.72 | 21.93 | 1.49 | 0.88 | 2.21 | -21.93 |
Gross Profit | -31.03 | -29.32 | -26.29 | 471.97 | 12.98 | 0.02 | -0.97 | 472.97 |
Gross Profit % | -137.5% | -236.94% | -182.09% | 95.56% | 89.73% | 2.02% | -77.75% | 95.76% |
| 111.68 | 44.92 | 47.33 | 103.59 | 55.46 | 54.74 | 60.78 | -32.61 | |
EBIT | -89.11 | -73.32 | -73.62 | 368.38 | -40.99 | -54.73 | -61.75 | 368.38 |
OPM % | -394.86% | -592.56% | -509.98% | 74.59% | -283.28% | -6128.44% | -4959.52% | 74.59% |
Non-Operating Income | 2.62 | 3.43 | 2.38 | 2.19 | 2.43 | 3.07 | 1.78 | 2.19 |
PBT | -86.49 | -69.89 | -71.24 | 370.57 | -38.56 | -51.66 | -59.97 | 370.57 |
Income Tax | 0 | 0.67 | 1.3 | 32.53 | 0 | 0.43 | -0.41 | -32.53 |
Tax Rate % | - | -0.95% | -1.83% | 8.78% | - | -0.83% | 0.68% | -8.78% |
Net Income | -86.65 | -70.55 | -72.54 | 338.04 | -32.76 | -52.08 | -59.56 | 338.04 |
NPM % | -383.98% | -570.22% | -502.51% | 68.44% | -226.42% | -5832.47% | -4783.94% | 68.44% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|
Revenue | 12.87 | 17.42 | 48.9 | 102.99 | 67.42 | 53.76 | 535.18 |
COGS | 17.74 | 27.98 | 14.17 | 238.19 | 183.99 | 124.37 | 105.83 |
Gross Profit | -4.87 | -10.57 | 34.73 | -135.21 | -116.57 | -70.61 | 429.35 |
Gross Profit % | -37.86% | -60.67% | 71.02% | -131.28% | -172.91% | -131.34% | 80.23% |
| 67.95 | 88.93 | 158.7 | 277.06 | 134.28 | 203.6 | 251.67 | |
EBIT | -72.82 | -99.5 | -124 | -412.26 | -249.46 | -274.21 | 177.68 |
OPM % | -565.8% | -571.3% | -253.58% | -400.29% | -370% | -510.08% | 33.2% |
Non-Operating Income | 1.69 | -0.63 | -5.8 | -0.23 | 0.3 | 14.24 | 13.2 |
PBT | -71.13 | -100.13 | -129.8 | -412.5 | -249.16 | -259.97 | 190.88 |
Income Tax | 0.11 | -0.25 | -0.73 | -0.78 | -0.13 | 0.2 | 28.7 |
Tax Rate % | -0.15% | 0.25% | 0.56% | 0.19% | 0.05% | -0.08% | 15.03% |
Net Income | -71.24 | -99.87 | -129.07 | -411.72 | -249.03 | -260.17 | 162.19 |
NPM % | -553.5% | -573.46% | -263.96% | -399.76% | -369.37% | -483.96% | 30.3% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| 21.38 | 30.68 | 1,322.59 | 811.46 | 495.8 | 402.45 | 481.75 | |
| 39.25 | 1.46 | 2.62 | 4.65 | 4.49 | 2.66 | 3.62 | |
| 40.47 | 61.69 | 100.59 | 200.39 | 0 | 0 | 0 | |
| 12.44 | 25.03 | 64.64 | 123.91 | 53.31 | 73.27 | 41.04 | |
| 12.12 | 11.76 | 20.91 | 17.83 | 306.88 | 309.87 | 276.41 | |
Total Assets | 125.66 | 130.62 | 1,511.36 | 1,158.24 | 860.47 | 788.25 | 802.83 |
| 0.73 | 0.73 | 21.66 | 22.45 | 23.4 | 26.88 | 26.92 | |
| 31.36 | -43.53 | 689.69 | 666.02 | 509.85 | 490.06 | 669.69 | |
| 0.08 | 79.15 | 30.09 | 28.89 | 42.09 | 41.82 | 38.97 | |
| 22.14 | 18.49 | 73.74 | 293.69 | 112.93 | 136.15 | 48.77 | |
| 71.36 | 75.78 | 696.18 | 147.19 | 172.2 | 93.33 | 18.48 | |
Total Liabilities | 125.66 | 130.62 | 1,511.36 | 1,158.24 | 860.47 | 788.25 | 802.83 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| -74.11 | -86.96 | 522.4 | -733.13 | -286.18 | -267.89 | 101.85 | |
| -4.26 | 28.18 | -45.27 | -127.9 | -93.5 | -55.2 | -18.44 | |
| -0.11 | 67.98 | 819.83 | 344.96 | 63.17 | 230.89 | -5.11 | |
Net CFNet Cash Flow | -78.49 | 9.2 | 1,296.96 | -516.07 | -316.5 | -92.19 | 78.29 |
FCFFree Cash Flow | -88.83 | -99.19 | 475.05 | -861.03 | -379.4 | -323.09 | 83.41 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| - | 1863.5% | -38.6% | -58.8% | -40.8% | -49.5% | 26.7% | |
| 0.00 | -1.85 | 0.04 | 0.04 | 0.08 | 0.08 | 0.06 | |
| 2.60 | 2.04 | 5.61 | 2.63 | 3.74 | 2.57 | 7.28 | |
| - | 0.14 | 0.06 | 0.08 | 0.07 | 0.07 | 0.67 | |
Cash Conversion | 1.04 | 0.87 | -4.05 | 1.78 | 1.15 | 1.03 | 0.63 |
Payout Ratio | - | - | - | - | - | - | - |
| - | 35.3% | 180.8% | 110.6% | -34.5% | -20.3% | 895.5% | |
| -0.39 | -0.54 | -0.70 | -2.20 | -1.30 | -1.16 | 0.72 | |
| - | - | -122.65 | -13.95 | -4.93 | -3.74 | 5.01 | |
| 2.00 | 3.00 | 6.00 | 2.00 | 3.00 | 2.00 | 7.00 | |
| - | -2.10 | -4.88 | 11.90 | 4.73 | 1.49 | 3.93 | |
| 33.33 | 0.00 | 66.67 | 33.33 | 33.33 | 33.33 | 85.00 | |
| -5.5% | -5.7% | -2.6% | -4.0% | -3.7% | -4.8% | 0.3% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns CureVac N.V., from SEC filings
Shares sold short · updated twice a month
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 31 Dec 2025 | 395,398 | -27.8% | 1.00 | |
| 15 Dec 2025 | 547,316 | -67.0% | 1.00 | |
| 28 Nov 2025 | 1,659,938 | +73.0% | 1.00 | |
| 14 Nov 2025 | 959,332 | +19.7% | 1.30 | |
| 31 Oct 2025 | 801,715 | -13.6% | 1.70 | |
| 15 Oct 2025 | 927,476 | -23.5% | 2.17 | |
| 30 Sep 2025 | 1,212,271 | +3.0% | 3.61 | |
| 15 Sep 2025 | 1,176,588 | +38.4% | 2.39 | |
| 29 Aug 2025 | 850,262 | +26.9% | 1.86 | |
| 15 Aug 2025 | 669,986 | -9.7% | 1.00 | |
| 31 Jul 2025 | 741,686 | -30.0% | 1.00 | |
| 15 Jul 2025 | 1,059,063 | +18.8% | 1.17 | |
| 30 Jun 2025 | 891,128 | -65.8% | 1.00 | |
| 13 Jun 2025 | 2,602,326 | -38.0% | 1.00 | |
| 30 May 2025 | 4,196,958 | -14.1% | 4.32 | |
| 15 May 2025 | 4,885,519 | -2.0% | 8.83 | |
| 30 Apr 2025 | 4,986,707 | +3.9% | 10.22 | |
| 15 Apr 2025 | 4,798,123 | -1.1% | 6.82 | |
| 31 Mar 2025 | 4,851,197 | +19.5% | 7.29 | |
| 14 Mar 2025 | 4,058,431 | +3.7% | 6.93 | |
| 28 Feb 2025 | 3,913,244 | +4.6% | 5.67 | |
| 14 Feb 2025 | 3,741,493 | +2.9% | 5.95 | |
| 31 Jan 2025 | 3,636,460 | -3.6% | 5.75 | |
| 15 Jan 2025 | 3,770,920 | -1.2% | 2.05 |
FINRA consolidated short interest, reported twice a month for every US listing.
CureVac N.V.'s SEC filings and earnings call transcripts
What recent news says about CureVac N.V., scored for sentiment.